Your browser is no longer supported. Please, upgrade your browser.
Oncternal Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.95 Insider Own14.82% Shs Outstand49.28M Perf Week-1.20%
Market Cap460.33M Forward P/E- EPS next Y-0.75 Insider Trans0.00% Shs Float43.50M Perf Month43.15%
Income-17.20M PEG- EPS next Q-0.10 Inst Own21.70% Short Float0.49% Perf Quarter74.26%
Sales3.40M P/S135.39 EPS this Y74.40% Inst Trans114.48% Short Ratio0.12 Perf Half Y366.67%
Book/sh3.83 P/B2.16 EPS next Y-53.10% ROA-38.50% Target Price- Perf Year180.95%
Cash/sh- P/C- EPS next 5Y0.00% ROE-46.40% 52W Range1.49 - 10.56 Perf YTD68.57%
Dividend- P/FCF- EPS past 5Y8.60% ROI-15.50% 52W High-21.78% Beta1.77
Dividend %- Quick Ratio20.10 Sales past 5Y- Gross Margin- 52W Low454.36% ATR0.93
Employees12 Current Ratio20.10 Sales Q/Q128.60% Oper. Margin- RSI (14)52.77 Volatility12.90% 12.27%
OptionableYes Debt/Eq0.00 EPS Q/Q67.80% Profit Margin- Rel Volume1.65 Prev Close9.34
ShortableYes LT Debt/Eq0.00 EarningsMar 11 AMC Payout- Avg Volume1.70M Price8.26
Recom1.70 SMA20-0.30% SMA5013.61% SMA200100.37% Volume2,795,351 Change-11.56%
Apr-07-21Initiated Oppenheimer Outperform $14
Feb-23-21Initiated Northland Capital Outperform $21
Apr-08-21 04:04AM  
Apr-05-21 08:34AM  
Mar-18-21 04:38PM  
Mar-15-21 06:12AM  
Mar-11-21 04:01PM  
Mar-04-21 08:00AM  
Feb-24-21 08:00AM  
Feb-22-21 05:33PM  
Jan-28-21 04:01PM  
Jan-14-21 08:00AM  
Jan-07-21 04:01PM  
Jan-05-21 08:00AM  
Dec-14-20 04:01PM  
Dec-09-20 11:50PM  
Dec-07-20 08:00AM  
Nov-30-20 06:14PM  
Nov-17-20 11:00PM  
Nov-11-20 08:00AM  
Nov-10-20 10:51AM  
Nov-09-20 04:01PM  
Nov-04-20 05:15PM  
Oct-06-20 08:00AM  
Sep-22-20 07:00AM  
Sep-21-20 08:00AM  
Sep-10-20 08:00AM  
Sep-03-20 08:29AM  
Aug-27-20 09:18PM  
Aug-06-20 04:15PM  
Jul-30-20 08:00AM  
Jul-27-20 08:00AM  
Jul-20-20 08:00AM  
Jun-30-20 08:00AM  
May-20-20 08:00AM  
May-19-20 08:00AM  
May-07-20 08:00AM  
May-05-20 08:00AM  
May-01-20 08:00AM  
Mar-18-20 08:36AM  
Mar-16-20 04:05PM  
Mar-11-20 04:08PM  
Feb-06-20 08:00AM  
Dec-12-19 06:00PM  
Dec-11-19 08:00AM  
Dec-09-19 08:00AM  
Dec-03-19 08:00AM  
Nov-21-19 08:00AM  
Nov-14-19 04:02PM  
Nov-11-19 08:00AM  
Nov-07-19 04:05PM  
Nov-05-19 08:00AM  
Oct-31-19 08:00AM  
Oct-03-19 08:00AM  
Sep-20-19 12:03PM  
Sep-17-19 04:05PM  
Sep-09-19 08:00AM  
Aug-28-19 04:01PM  
Aug-08-19 04:01PM  
Aug-06-19 08:00AM  
Aug-01-19 04:01PM  
Jun-10-19 08:00AM  
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARTER MICHAEL GDirectorSep 01Buy2.1071,429150,00171,947Sep 02 04:53 PM
AKER HAZEL MLegal CounselJul 21Buy2.3841,97299,99846,987Jul 23 05:00 PM
KISNER DANIEL LDirectorJul 21Buy2.3810,00023,82510,000Jul 23 05:00 PM
Shanghai Pharmaceutical (USA) 10% OwnerJul 21Buy2.381,049,3172,499,9983,544,431Jul 23 04:32 PM